已核实 DOI PubMed 相关产品: 2

Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity

Journal 2018 · IF 3.296 · 发表于 2018 年 10 月 25 日
作者: Xinxin Han,Ning Wang,Junya Li,Ying Wang,Ruiyong Wang,Junbiao Chang
阅读全文 在 PubMed 查看

摘要

Nafamostat mesilate is a serine protease inhibitor and used for the treatment of pancreatitis and cancers. The fat mass and obesity-associated protein (FTO) was identified to be a demethylase and played an important role in physiological processes. The aim of this study was to examine the inhibition of Nafamostat mesilate on FTO demethylase activity. A combination of thermodynamic and enzymatic activity studies provides an insight into the recognition of Nafamostat mesilate by FTO. The binding of Nafamostat mesilate to FTO was driven by higher positive entropy changes and smaller negative enthalpy changes. The structural and thermodynamic information provides the basis for the design of more effective inhibitors for FTO. Our results might provide a novel target protein for Nafamostat mesilate.

本研究中使用的阿拉丁产品

2 款产品在本文中被引用